Milestones

Since 1983, we have imagined a healthier, better world, believing that together we can invest to make a difference in people’s lives. In 2018, we celebrated our 35 years of commitment.

1980-1990

1983

Wolfgang Marguerre establishes Octapharma with a single idea: people with haemophilia deserve access to better products.

1985

The first factor VIII medicine, octavi®, is launched.

Celebrating 35 years - 1990-2000

1990

Opens first state-of-the-art manufacturing site, acquired from Schwab in Vienna, Austria.

1992

Establishes laboratory in Frankfurt for validation and documentation of virus inactivation methods.

1999

Acquires second manufacturing site from Aventis in Lingolsheim, France, to increase capacity.

Celebrating 35 years - 2000-2010

2002

Acquires third manufacturing site from Biovitrum in Stockholm, Sweden, to increase product portfolio.

2003

Expands into US market with FDA registration of octagam®.

2006

Acquires five plasma donation centres in Germany from Deutsche Gesellschaft für Humanplasma.

2007

Octapharma Plasma Inc. founded in the US to operate our own plasma donation centres.

2008

Acquires fourth state-of-the-art manufacturing site from German Red Cross in Springe, Hanover, Germany.

Celebrating 35 years - 2010-2020

2012

Opens the Institute for Recombinant Protein Research & Development in Heidelberg, Germany, to further invest in innovative therapies.

2014

European Medicines Agency (EMA) approves our first recombinant product for haemophilia A patients, Nuwiq®.

2015

FDA approves Nuwiq® for haemophilia A patients in the USA.

2016

panzyga® receives regulatory approval in Canada and the EU for primary immunodeficiency syndromes and primary immune thrombocytopenia.

2017

Fibryga® receives marketing authorization for congenital fibrinogen deficiency in 16 EU countries, the US and Canada.

2018

Octapharma announces promising pre-clinical data for SubQ-8, our recombinant FVIII in development for subcutaneous administration.